CN113880952A - 自然杀伤细胞接合抗体融合构建体 - Google Patents

自然杀伤细胞接合抗体融合构建体 Download PDF

Info

Publication number
CN113880952A
CN113880952A CN202111125559.3A CN202111125559A CN113880952A CN 113880952 A CN113880952 A CN 113880952A CN 202111125559 A CN202111125559 A CN 202111125559A CN 113880952 A CN113880952 A CN 113880952A
Authority
CN
China
Prior art keywords
cd16a
seq
antigen
antigen binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111125559.3A
Other languages
English (en)
Chinese (zh)
Inventor
米夏埃多·特萨
克里斯蒂娜·埃尔万格尔
伊维察·富切克
乌韦·罗伊施
托尔斯滕·罗斯
约阿希姆·科赫
埃里希·拉伊科维奇
梅尔廷·特雷德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiffermed Co ltd
Affimed GmbH
Original Assignee
Eiffermed Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiffermed Co ltd filed Critical Eiffermed Co ltd
Publication of CN113880952A publication Critical patent/CN113880952A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202111125559.3A 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体 Pending CN113880952A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18167384.9 2018-04-13
EP18167385 2018-04-13
EP18167385.6 2018-04-13
EP18167384 2018-04-13
EP18190661 2018-08-24
EP18190661.1 2018-08-24
EP18190662.9 2018-08-24
EP18190662 2018-08-24
CN201980033176.8A CN112119097B (zh) 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980033176.8A Division CN112119097B (zh) 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体

Publications (1)

Publication Number Publication Date
CN113880952A true CN113880952A (zh) 2022-01-04

Family

ID=66625219

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111125559.3A Pending CN113880952A (zh) 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体
CN202111125475.XA Pending CN113817066A (zh) 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体
CN201980033176.8A Active CN112119097B (zh) 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202111125475.XA Pending CN113817066A (zh) 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体
CN201980033176.8A Active CN112119097B (zh) 2018-04-13 2019-04-12 自然杀伤细胞接合抗体融合构建体

Country Status (21)

Country Link
US (3) US11001633B2 (https=)
EP (1) EP3774914A2 (https=)
JP (2) JP2021521275A (https=)
KR (1) KR20200143436A (https=)
CN (3) CN113880952A (https=)
AU (2) AU2019252970A1 (https=)
BR (1) BR112020020828A2 (https=)
CA (1) CA3095373A1 (https=)
CL (2) CL2020002625A1 (https=)
CO (1) CO2020014167A2 (https=)
CR (1) CR20200549A (https=)
IL (1) IL277925A (https=)
MA (1) MA52227A (https=)
MX (1) MX2020010728A (https=)
PE (1) PE20201346A1 (https=)
PH (1) PH12020551664B1 (https=)
RU (1) RU2022105827A (https=)
SG (1) SG11202010064QA (https=)
TW (1) TW202012441A (https=)
WO (1) WO2019198051A2 (https=)
ZA (1) ZA202006325B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
EP4073117A1 (en) * 2019-12-10 2022-10-19 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
JP7620780B2 (ja) * 2020-06-30 2025-01-24 ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
WO2022098972A1 (en) * 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
US20250277024A1 (en) * 2020-12-03 2025-09-04 Amgen Inc. Molecules with multiple binding domains
JP2024503933A (ja) * 2021-01-27 2024-01-29 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
EP4405379A4 (en) * 2021-09-24 2025-08-20 Synergy Imt Inc COMPOSITION OF RECOMBINANT ANTIGEN-BINDING MOLECULES AND METHOD OF MANUFACTURE AND USE THEREOF
US20260070986A1 (en) 2021-11-03 2026-03-12 Affimed Gmbh Bispecific cd16a binders
IL312515A (en) 2021-11-03 2024-07-01 Affimed Gmbh Bispecific cd16a binders
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
CN119923415A (zh) * 2022-08-05 2025-05-02 成都恩沐生物科技有限公司 靶向可二聚化肿瘤抗原和免疫刺激性抗原的多特异性抗体
CN120035609A (zh) * 2022-09-14 2025-05-23 大塚制药株式会社 Pd-1激动剂抗体
CN120641128A (zh) * 2023-02-06 2025-09-12 乐普创一生物科技（上海）有限公司 抗cd16a抗体及其用途
KR20240136856A (ko) * 2023-03-06 2024-09-19 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2025257588A1 (en) * 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
CN105367660A (zh) * 2015-12-22 2016-03-02 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
JP2018509175A (ja) * 2014-12-22 2018-04-05 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 二重特異性四価抗体並びにその製作及び使用方法
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
EP2361936B1 (en) * 2010-02-25 2016-04-20 Affimed GmbH Antigen-binding molecule and uses thereof
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2825557B1 (en) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
RU2016132863A (ru) * 2014-01-15 2018-02-20 Займворкс Инк. БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ
LT3292153T (lt) * 2015-05-04 2019-11-11 Affimed Gmbh Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
JP2018509175A (ja) * 2014-12-22 2018-04-05 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 二重特異性四価抗体並びにその製作及び使用方法
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660A (zh) * 2015-12-22 2016-03-02 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
CN110382539A (zh) * 2017-02-28 2019-10-25 阿菲姆德股份有限公司 用于cd16a定向的nk细胞结合的串联双抗体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GANTKE 等: "AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma", 59TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH), 7 December 2017 (2017-12-07), pages 3082, XP086634756, DOI: 10.1182/blood.V130.Suppl_1.3082.3082 *
GANTKE 等: "Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells", PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 30, no. 9, 1 September 2017 (2017-09-01), XP055595613, DOI: 10.1093/protein/gzx043 *
SCHOONJANS 等: "Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives", THE JOURNAL OF IMMUNOLOGY, vol. 165, no. 12, 15 December 2000 (2000-12-15), XP002207879 *
SPIESS 等: "Alternative molecular formats and therapeutic applications for bispecific antibodies", MOLECULAR IMMUNOLOGY, vol. 67, 27 January 2015 (2015-01-27), pages 1 *
陆寒 等: "新型抗ErbB2、抗CD16三价双特异性抗体的构建及功能鉴定", 西安交通大学学报(医学版), no. 05, 15 October 2008 (2008-10-15), pages 7 *

Also Published As

Publication number Publication date
CO2020014167A2 (es) 2021-04-08
WO2019198051A3 (en) 2019-11-14
PH12020551664A1 (en) 2021-12-13
ZA202006325B (en) 2025-12-17
US20210253698A1 (en) 2021-08-19
SG11202010064QA (en) 2020-11-27
MX2020010728A (es) 2020-11-06
AU2026200541A1 (en) 2026-02-19
CA3095373A1 (en) 2019-10-17
BR112020020828A2 (pt) 2021-01-19
AU2019252970A1 (en) 2020-11-26
CN112119097B (zh) 2021-10-15
PH12020551664B1 (en) 2023-05-19
WO2019198051A2 (en) 2019-10-17
CL2023001085A1 (es) 2023-10-06
US20240294647A1 (en) 2024-09-05
US11001633B2 (en) 2021-05-11
MA52227A (fr) 2021-04-21
CN113817066A (zh) 2021-12-21
CR20200549A (es) 2021-03-18
RU2022105827A (ru) 2022-04-05
CL2020002625A1 (es) 2021-02-19
KR20200143436A (ko) 2020-12-23
JP2025081307A (ja) 2025-05-27
JP2021521275A (ja) 2021-08-26
IL277925A (en) 2020-11-30
US20200109202A1 (en) 2020-04-09
TW202012441A (zh) 2020-04-01
PE20201346A1 (es) 2020-11-25
EP3774914A2 (en) 2021-02-17
CN112119097A (zh) 2020-12-22

Similar Documents

Publication Publication Date Title
CN112119097B (zh) 自然杀伤细胞接合抗体融合构建体
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
US11377477B2 (en) PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
JP6971153B2 (ja) 多重特異的ｎｋエンゲイジャータンパク質
AU2018228719B2 (en) Tandem diabody for CD16A-directed NK-cell engagement
JP2019533444A (ja) ＩＬ−１５／ＩＬ−１５ＲアルファＦｃ融合タンパク質およびＰＤ−１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
JP2017521400A (ja) 多重特異的ＮＫｐ４６結合タンパク質
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
CN114127112A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
TW202235104A (zh) 雙功能分子
US20250215081A1 (en) Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN119365490A (zh) 结合pd-l1、pd-l2和/或cd28的抗体
WO2022063819A1 (en) Novel human antibodies binding to human cd3 epsilon
RU2774711C2 (ru) Слитые конструкции антител для вовлечения nk-клеток
HK40034204B (en) Nk cell engaging antibody fusion constructs
HK40034204A (en) Nk cell engaging antibody fusion constructs
HK40066389A (zh) 自然杀伤细胞接合抗体融合构建体
HK40066055A (zh) 自然杀伤细胞接合抗体融合构建体
HK40016394B (zh) 双特异性检查点抑制剂抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066055

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220104